CTRI/2013/12/004227
Other
Phase 4
GLucobay M - Evaluation Of Safety and Effectiveness in Type 2 Diabetes Not Well Controlled on Monotherapy in Real Life Practice - GLORY
Bayer Zydus Pharma0 sites10,000 target enrollmentTBD
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Health Condition 1: null- Type-2 Diabetes
- Sponsor
- Bayer Zydus Pharma
- Enrollment
- 10000
- Status
- Other
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient will be enrolled after the decision to administer acarbose/metformin fixed dose combination for type\-2 diabetes management has been made by the attending physician on the basis of best clinical practice and patient needs.
- •Willing to give informed consent for participating in this study
Exclusion Criteria
- •Patients receiving anti\-diabetic medication other than acarbose, or metformin monotherapy at the time of enrollment in the study will be excluded. However, during observation period, any additional anti\-diabetics medication administered by the attending physician will be allowed \& recorded in case record form.
- •Patient receiving acarbose/metformin fixed dose combination during 3\-months prior to enrollment.
- •Exclusion criteria should be read in conjunction with local product information
Outcomes
Primary Outcomes
Not specified
Similar Trials
Withdrawn
Not Applicable
GLucobay M - Evaluation Of Safety and Effectiveness in Type 2 Diabetes Not Well Controlled on Monotherapy in Real Life PracticeDiabetes Mellitus, Type 2NCT01915264Bayer
Completed
Phase 2
Clinical study on Kumkumadi Ghrit in Facial dark patches.Health Condition 1: L819- Disorder of pigmentation, unspecifiedCTRI/2022/06/043272amaskar Ayurved Private Limited36
Recruiting
Not Applicable
Investigation for efficacy and safety of [18F] EST-604JPRN-jRCTs031230644Tagai Kenji36
Completed
Not Applicable
GLucobay M OBservation Study for Efficacy and Safety in Treatment of Type-2 Diabetes PatientsType 2 DiabetesNCT01219582Bayer9,364
Completed
Phase 1
Examination of the effectiveness and safety of multidisciplinary therapy with docetaxel for high-risk prostate cancerprostate cancerJPRN-UMIN000023145Juntendo University Hospital100